Cited 0 times in
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2024-02-15T07:00:00Z | - |
dc.date.available | 2024-02-15T07:00:00Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.issn | 0284-186X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198110 | - |
dc.description.abstract | Background: In the single-arm CHRYSALIS trial, advanced non-small cell lung cancer patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon 20ins) showed durable responses to amivantamab, an EGFR-MET bispecific antibody targeting tumors with EGFR Exon 20ins. This study compared the effectiveness of amivantamab to real-world systemic anti-cancer therapies in Japan. Patients and methods: External control patients were selected by applying CHRYSALIS eligibility to Japanese patients from LC-SCRUM-Asia. External control patients were included for every qualifying line of therapy after platinum-based chemotherapy. Propensity score weighting was applied to external control patients to adjust for differences in baseline characteristics. Outcomes were compared between external control patients, and all and Asian-only CHRYSALIS patients using weighted Cox proportional hazards regression models for progression-free survival (PFS), time to next therapy (TTNT), and overall survival (OS), and generalized estimating equations with repeated measurements for overall response rate (ORR). Results: One hundred fifteen CHRYSALIS and 94 external control patients were identified. Compared to external control patients, amivantamab-treated patients had significantly longer OS (median OS 19.88 vs 14.09 months, HR [95% CI] 0.59 [0.40–0.88]), PFS (median PFS 6.74 vs 4.73 months, HR 0.59 [0.45–0.78]), TTNT (median TTNT 12.16 vs 5.09 months, HR 0.39 [0.29–0.53]), and significantly higher ORR (41.7% vs 14.1%). Analyses of amivantamab-treated Asian patients (n = 61) showed similar clinical benefits. Conclusion: In the absence of clinical evidence from randomized clinical trials, this study reflects the benefit of amivantamab after platinum-based chemotherapy for advanced non-small cell lung cancer patients harboring EGFR Exon 20ins, compared to current real-world therapies. © 2023 Janssen Asia Pacific, a division of Johnson and Johnson International (Singapore) Pte Ltd. Published by Informa UK Limited, trading as Taylor & Francis Group. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Informa Healthcare | - |
dc.relation.isPartOf | ACTA ONCOLOGICA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / drug therapy | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / genetics | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / pathology | - |
dc.subject.MESH | ErbB Receptors / genetics | - |
dc.subject.MESH | Exons / genetics | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms* / drug therapy | - |
dc.subject.MESH | Lung Neoplasms* / genetics | - |
dc.subject.MESH | Lung Neoplasms* / pathology | - |
dc.subject.MESH | Mutagenesis, Insertional | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Platinum / therapeutic use | - |
dc.subject.MESH | Protein Kinase Inhibitors / therapeutic use | - |
dc.title | Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Tae Min Kim | - |
dc.contributor.googleauthor | Nicolas Girard | - |
dc.contributor.googleauthor | Grace Kah Mun Low | - |
dc.contributor.googleauthor | Jianmin Zhuo | - |
dc.contributor.googleauthor | Dae Young Yu | - |
dc.contributor.googleauthor | Yishen Yang | - |
dc.contributor.googleauthor | Maiko Murota | - |
dc.contributor.googleauthor | Cindy Thiow Koon Lim | - |
dc.contributor.googleauthor | Nora J Kleinman | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.identifier.doi | 10.1080/0284186X.2023.2254479 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J00024 | - |
dc.identifier.eissn | 1651-226X | - |
dc.identifier.pmid | 37938161 | - |
dc.subject.keyword | CHRYSALIS trial | - |
dc.subject.keyword | EGFR exon 20 insertions | - |
dc.subject.keyword | LC-SCRUM-Asia | - |
dc.subject.keyword | amivantamab | - |
dc.subject.keyword | external control | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.citation.volume | 62 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1689 | - |
dc.citation.endPage | 1697 | - |
dc.identifier.bibliographicCitation | ACTA ONCOLOGICA, Vol.62(12) : 1689-1697, 2023-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.